RELEASE DATE: December 2, 2021
Ochsner Health and the MMRF are launching an innovative research collaboration to drive precision medicine approaches to myeloma treatment. The collaboration centers around the MMRF CureCloud, a groundbreaking, direct-to-patient research study designed to collect deidentified data from 5000 myeloma patients. The data will be made available to researchers to accelerate cures for each and every myeloma patient, while providing genomic sequencing results to patients and to their doctors. In the CureCloud research study,
- Patients provide a liquid biopsy (blood sample) and receive genomic sequencing of their myeloma at no cost to them
- Results of this sequencing are returned both to physicians and to their patients. The reports will list clinical trials that may be appropriate for the patient based on their sequencing results
- Clinical outcomes data are collected from the patient’s electronic medical record and updated every 6 months
- Patients will be followed over 10 years and additional liquid biopsies will be collected at each relapse
- Genomic and clinical data are connected to each other in the secure CureCloud database to provide a complete picture of each patient’s myeloma.
More information about the MMRF is available at www.themmrf.org.